4/22
09:34 am
axsm
15 Most Black States in the US [Yahoo! Finance]
Medium
Report
15 Most Black States in the US [Yahoo! Finance]
4/17
09:00 pm
axsm
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Medium
Report
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
4/15
07:10 am
axsm
Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting [Yahoo! Finance]
Low
Report
Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting [Yahoo! Finance]
4/15
07:09 am
axsm
Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting [Financial Post (Toronto, Ontario, Canada)]
Low
Report
Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting [Financial Post (Toronto, Ontario, Canada)]
4/15
07:00 am
axsm
Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting
Low
Report
Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting
4/12
02:30 am
axsm
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Medium
Report
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
4/10
10:19 am
axsm
Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $107.00 price target on the stock.
Low
Report
Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $107.00 price target on the stock.
4/10
07:00 am
axsm
Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6
Low
Report
Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6
4/3
09:00 pm
axsm
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Low
Report
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
4/2
09:01 am
axsm
Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $190.00 price target on the stock.
Medium
Report
Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $190.00 price target on the stock.
4/1
07:06 am
axsm
Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder [Yahoo! Finance]
Medium
Report
Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder [Yahoo! Finance]
4/1
07:04 am
axsm
Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder [Financial Post (Toronto, Ontario, Canada)]
Low
Report
Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder [Financial Post (Toronto, Ontario, Canada)]
4/1
07:00 am
axsm
Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder
Low
Report
Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder
3/28
10:51 am
axsm
XPH: A More Balanced Way To Get Exposure To Pharmaceuticals [Seeking Alpha]
Low
Report
XPH: A More Balanced Way To Get Exposure To Pharmaceuticals [Seeking Alpha]
3/26
01:02 pm
axsm
Axsome's (AXSM) Narcolepsy Drug Study Meets Primary Goal [Yahoo! Finance]
Low
Report
Axsome's (AXSM) Narcolepsy Drug Study Meets Primary Goal [Yahoo! Finance]
3/26
09:33 am
axsm
Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $150.00 price target on the stock.
Low
Report
Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $150.00 price target on the stock.
3/26
08:13 am
axsm
Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its price target raised by analysts at HC Wainwright from $180.00 to $190.00. They now have a "buy" rating on the stock.
Low
Report
Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its price target raised by analysts at HC Wainwright from $180.00 to $190.00. They now have a "buy" rating on the stock.
3/26
08:12 am
axsm
Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its price target raised by analysts at Citigroup Inc. from $125.00 to $127.00. They now have a "buy" rating on the stock.
Low
Report
Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its price target raised by analysts at Citigroup Inc. from $125.00 to $127.00. They now have a "buy" rating on the stock.
3/26
08:11 am
axsm
Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its price target raised by analysts at Royal Bank of Canada from $123.00 to $128.00. They now have an "outperform" rating on the stock.
Low
Report
Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its price target raised by analysts at Royal Bank of Canada from $123.00 to $128.00. They now have an "outperform" rating on the stock.
3/26
06:44 am
axsm
30 Countries with the Lowest Depression Rates [Yahoo! Finance]
Low
Report
30 Countries with the Lowest Depression Rates [Yahoo! Finance]
3/25
09:00 pm
axsm
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Low
Report
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
3/25
09:41 am
axsm
Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients [Financial Post (Toronto, Ontario, Canada)]
Medium
Report
Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients [Financial Post (Toronto, Ontario, Canada)]
3/25
09:41 am
axsm
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy [Financial Post (Toronto, Ontario, Canada)]
Medium
Report
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy [Financial Post (Toronto, Ontario, Canada)]
3/25
07:05 am
axsm
Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients [Yahoo! Finance]
High
Report
Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients [Yahoo! Finance]
3/25
07:00 am
axsm
Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients
High
Report
Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients